Osteocyte RANKL: New insights into the control of bone remodeling

Journal of Bone and Mineral Research

Volumn 27, Issue 3, 2012, Pages 499-505

  Xiong, Jinhu ^a,b   O'Brien, Charles A ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

BONE REMODELING; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

BONE REMODELING; CANCELLOUS BONE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; PROTEIN EXPRESSION; REVIEW; STEM CELL;

ANIMALS; BIOMECHANICS; BONE REMODELING; HORMONES; HUMANS; OSTEOCYTES; RANK LIGAND;

EID: 84857311721     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1547     Document Type: Review

References (78)

1. Bonewald LF., The amazing osteocyte. J Bone Miner Res. 2011; 26: 229-38.
2. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE., Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38: 1310-5.
3. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA., Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem. 2003; 278: 1998-2007.
4. Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J., Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68: 577-89.
5. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W., Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10: 537-43.
6. Balemans W, Patel N, Ebeling M, Van HE, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lindpaintner K, Vickery B, Foernzler D, Van Hul W., Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002; 39: 91-7.
7. Staehling-Hampton K, Proll S, Paeper BW, Zhao L, Charmley P, Brown A, Gardner JC, Galas D, Schatzman RC, Beighton P, Papapoulos S, Hamersma H, Brunkow ME., A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002; 110: 144-52.
8. Van Bezooijen RL, Roelen BAJ, Visser A, Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CWGM., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004; 199: 805-14.
9. Yang W, Lu Y, Kalajzic I, Guo D, Harris MA, Gluhak-Heinrich J, Kotha S, Bonewald LF, Feng JQ, Rowe DW, Turner CH, Robling AG, Harris SE., Dentin matrix protein 1 gene cis-regulation: use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo. J Biol Chem. 2005; 280: 20680-90.
10. Lu Y, Xie Y, Zhang S, Dusevich V, Bonewald LF, Feng JQ., DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res. 2007; 86: 320-5.
11. Kalajzic I, Braut A, Guo D, Jiang X, Kronenberg MS, Mina M, Harris MA, Harris SE, Rowe DW., Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone. 2004; 35: 74-82.
12. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H., Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231-4.
13. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA., Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17: 1235-41.
14. Rodan GA, Martin TJ., Role of osteoblasts in hormonal control of bone resorption-a hypothesis. Calcif Tissue Int. 1981; 33: 349-51.
15. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T., Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988; 123: 2600-2.
16. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ, Suda T., The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology. 1989; 125: 1805-13.
17. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165-76.
18. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998; 95: 3597-602.
19. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD., The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990; 345: 442-4.
20. Karsenty G, Kronenberg HM, Settembre C., Genetic control of bone formation. Annu Rev Cell Dev Biol. 2009; 25: 629-48.
21. Manolagas SC., Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21: 115-37.
22. Corral DA, Amling M, Priemel M, Loyer E, Fuchs S, Ducy P, Baron R, Karsenty G., Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci USA. 1998; 95: 13835-40.
23. Galli C, Fu Q, Wang W, Olsen BR, Manolagas SC, Jilka RL, O'Brien CA., Commitment to the osteoblast lineage is not required for RANKL gene expression. J Biol Chem. 2009; 284: 12654-62.
24. Otsuka E, Notoya M, Hagiwara H., Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif Tissue Int. 2003; 73: 72-7.
25. Ghosh-Choudhury N, Singha PK, Woodruff K, St. Clair P, Bsoul S, Werner SL, Choudhury GG., Concerted action of Smad and CREB-binding protein regulates bone morphogenetic protein-2-stimulated osteoblastic colony-stimulating factor-1 expression. J Biol Chem. 2006; 281: 20160-70.
26. Zhao S, Kato Y, Zhang Y, Harris S, Ahuja SS, Bonewald LF., MLO-Y4 osteocyte-like cells support osteoclast formation and activation. J Bone Miner Res. 2002; 17: 2068-79.
27. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL., The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000; 141: 4768-76.
28. Atkins GJ, Kostakis P, Pan BQ, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino ACW., RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res. 2003; 18: 1088-98.
29. Thomas GP, Baker SU, Eisman JA, Gardiner EM., Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J Endocrinol. 2001; 170: 451-60.
30. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA., PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004; 19: 235-44.
31. Kartsogiannis V, Zhou H, Horwood NJ, Thomas RJ, Hards DK, Quinn JMW, Niforas P, Ng KW, Martin TJ, Gillespie MT., Localization of RANKL (Receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999; 25: 525-34.
32. Silvestrini G, Ballanti P, Patacchioli F, Leopizzi M, Gualtieri N, Monnazzi P, Tremante E, Sardella D, Bonucci E., Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol. 2005; 36: 59-67.
33. Ikeda T, Utsuyama M, Hirokawa K., Expression profiles of receptor activator of nuclear factor kappa B ligand, receptor activator of nuclear factor kappa B, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res. 2001; 16: 1416-25.
34. Logan M, Martin JF, Nagy A, Lobe C, Olson EN, Tabin CJ., Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis. 2002; 33: 77-80.
35. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397: 315-23.
36. Rodda SJ, McMahon AP., Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development. 2006; 133: 3231-44.
37. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL., Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002; 277: 44005-12.
38. Gebhard S, Hattori T, Bauer E, Schlund B, Bosl MR, de Crombrugghe B, von der Mark K., Specific expression of Cre recombinase in hypertrophic cartilage under the control of a BAC-Col10a1 promoter. Matrix Biol. 2008; 27: 693-9.
39. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K., Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007; 5: 464-75.
40. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S., Remodeling and vascular spaces in bone. J Bone Miner Res. 2007; 22: 1-6.
41. Wang L, Liu Y, Kalajzic Z, Jiang X, Rowe DW., Heterogeneity of engrafted bone-lining cells after systemic and local transplantation. Blood. 2005; 106: 3650-7.
42. Kim S, Pajevic PD, Seling M, Kronenberg H., Intermittent PTH of short term can activate quiescent lining cells to mature osteoblasts: unproven mechanism of the anabolic action of intermittent PTH. J Bone Miner Res. 2010; 25: S46.
43. Kurata K, Heino TJ, Higaki H, Vaananen HK., Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res. 2006; 21: 616-25.
44. Mizuno A, Kanno T, Hoshi M, Shibata O, Yano K, Fujise N, Kinosaki M, Yamaguchi K, Tsuda E, Murakami A, Yasuda H, Higashio K., Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab. 2002; 20: 337-44.
45. Kamioka H, Honjo T, Takano-Yamamoto T., A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone. 2001; 28: 145-9.
46. Robling AG, Castillo AB, Turner CH., Biomechanical and molecular regulation of bone remodeling. Annu Rev Biomed Eng. 2006; 8: 455-98.
47. Forwood MR., Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res. 1996; 11: 1688-93.
48. Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, Mantila SM, Gluhak-Heinrich J, Bellido TM, Harris SE, Turner CH., Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283: 5866-75.
49. Aguirre J, Buttery L, O'Shaughnessy M, Afzal F, Fernandez de Marticorena I, Hukkanen M, Huang P, MacIntyre I, Polak J., Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. Am J Pathol. 2001; 158: 247-57.
50. Aguirre JI, Plotkin LI, Stewart SA, Weinstein RS, Parfitt AM, Manolagas SC, Bellido T., Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res. 2006; 21: 605-15.
51. Verborgt O, Gibson GJ, Schaffler MB., Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res. 2000; 15: 60-7.
52. Cardoso L, Herman BC, Verborgt O, Laudier D, Majeska RJ, Schaffler MB., Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res. 2009; 24: 597-605.
53. Al-Dujaili SA, Lau E, Al-Dujaili H, Tsang K, Guenther A, You L., Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem. 2011; 112: 2412-23.
54. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, Suda T., In vivo administration of 1,25-dihydroxyvitamin D-3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem. 2003; 90: 267-77.
55. Miao DS, He B, Lanske B, Bai XY, Tong XK, Hendy GN, Goltzman D, Karaplis AC., Skeletal abnormalities in Pth-null mice are influenced by dietary calcium. Endocrinology. 2004; 145: 2046-53.
56. Fu Q, Jilka RL, Manolagas SC, O'Brien CA., Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem. 2002; 277: 48868-75.
57. Fu Q, Manolagas SC, O'Brien CA., Parathyroid hormone controls receptor activator of NF-κB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006; 26: 6453-68.
58. Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, Manolagas SC, O'Brien CA., Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology. 2008; 149: 146-53.
59. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T., Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE. 2008; 3: e2942.
60. Tu X, Edwards R, Olivos N, Benson J, Galli C, Pellegrini G, Bivi N, Plotkin L, Bellido T., Conditional deletion of the parathyroid hormone (PTH) receptor 1 from osteocytes results in decreased bone resorption and a progressive increase in cancellous bone mass. J Bone Miner Res. 2011; 26: S16.
61. Saini V, Barry K, Fulzele K, Feng J, Divieti PP., PTH/PTHrP (PPR) Receptor signaling in osteocytes regulate bone development in temporal manner. J Bone Miner Res. 2011; 26: S16.
62. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S., Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 2007; 130: 811-23.
63. Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC., The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010; 24: 323-34.
64. Tomkinson A, Reeve J, Shaw RW, Noble BS., The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997; 82: 3128-35.
65. Emerton KB, Hu B, Woo AA, Sinofsky A, Hernandez C, Majeska RJ, Jepsen KJ, Schaffler MB., Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone. 2010; 46: 577-83.
66. Tomkinson A, Gevers EF, Wit JM, Reeve J, Noble BS., The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res. 1998; 13: 1243-50.
67. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC., Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001; 104: 719-30.
68. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC., Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002; 298: 843-6.
69. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL., Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003; 111: 1221-30.
70. Onal M, Xiong J, Cazer P, Manolagas S, O'Brien C., RANKL production by B lymphocytes contributes to the bone loss induced by inflammation and ovariectomy. J Bone Miner Res. 2011; 26: S142.
71. Proell V, Xu H, Schuler C, Weber K, Hofbauer LC, Erben RG., Orchiectomy upregulates free soluble RANKL in bone marrow of aged rats. Bone. 2009; 45: 677-81.
72. Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D, Adamu S, Ke HZ, Simonet WS, Kostenuik PJ., Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone. 2009; 45: 669-76.
73. Parfitt AM., Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone. 2002; 30: 5-7.
74. Parfitt AM., Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. [Review] [52 refs]. J Cell Biochem. 1994; 55: 273-86.
75. Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC., Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010; 25: 2427-37.
76. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL., Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577-83.
77. Poole KE, Van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J., Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19: 1842-4.
78. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ., Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway. PLoS One. 2011; 6: e25900.